Yilabuvir Sodium

英莱布韦钠

Report date: 2022/09/07 17:52:10
NME

Base Information

Drug NameYilabuvir Sodium
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYichang Hec Changjiang Pharmaceutical Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis C, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A